Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy

Bone Marrow Transplantation

Volumn 40, Issue 3, 2007, Pages 209-217

  Saito, A M ^a   Zahrieh, D ^a   Cutler, C ^a   Ho, V T ^a   Antin, J H ^a   Soiffer, R J ^a   Alyea, E P ^a   Lee, S J ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; METHOTREXATE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CHILD; COSTS AND COST ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34547235568     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705733     Document Type: Article

References (39)

1. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000; 5: 215-223.
4. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
5. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
6. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777-2785.
7. Nusair S, Breuer R, Shapira MY, Berkman N, Or R. Low incidence of pulmonary complications following nonmyeloablative stem cell transplantation. Eur Respir J 2004; 23: 440-445.
8. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
9. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
10. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
11. Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: A systematic review. Cancer Control 2003; 10: 17-41.
12. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588.
13. Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Jakobsen BK, Sengelov H et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: Results, complications and admission requirements in a single institution. Br J Haematol 2004; 125: 225-231.
14. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
15. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001; 938: 328-337; discussion 337-9.
16. Svahn BM, Bjurman B, Myrback KE, Aschan J, Ringden O. Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase?. A pilot trial. Presse Med 2004; 33: 474-478.
17. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
18. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
19. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
20. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006; 20: 128-135.
21. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.
22. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
23. Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996; 34 (12 Suppl): DS197-DS199.
24. Hsiao WC, Braun P, Yntema D, Becker ER. Estimating physicians' work for a resource-based relative-value scale. N Engl J Med 1988; 319 835-841.
25. Bureau of Labor Statistics. Consumer Price Index (available at http://wwwbls.gov, accessed March 1, 2005).
26. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
27. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
29. Greenwood M. A Report on the Natural Duration of Cancer Reports in Public Health and Medical Subjects, Ministry of Health 33. HMSO: London, 1926, pp 1-26.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
31. Cox DR. Regression models and life tables (with discussion). J R Statist Soc B 1972; 34: 187-220.
32. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70 41-55.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1998; 16 1141-1154.
34. Cox DR. Analysis of Binary Data. Methuen and Co.: London, UK, 1970.
35. Wilcoxon FI. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
36. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
37. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-414.
38. Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649-654.
39. Wright JR, Bouma S, Dayes I, Sussman J, Simunovic MR, Levine MN et al. The importance of reporting patient recruitment details in phase III trials. J Clin Oncol 2006; 24: 843-845.